TRP_1170x120_3-8-19

Cordis

Cardinal Health closes Cordis acquisition

Cardinal Health closes Cordis acquisition

DUBLIN, Ohio — Cardinal Health has completed its acquisition of Johnson & Johnson’s Cordis cardiology and endovascular device business for $1.944 billion. Cardinal said Sunday evening that the integration of Cordis off to a strong start, with management teams in place worldwide. The company noted that planning has been ongoing since the deal was announced

Cardinal Health wraps up purchase of Harvard Drug

Cardinal Health wraps up purchase of Harvard Drug

DUBLIN, Ohio — Cardinal Health Inc. has closed its $1.115 billion acquisition of pharmaceutical distributor Harvard Drug Group. Cardinal said Monday that the all-cash deal, announced in early June, will boost its generic drug distribution business as well as expand its over-the counter drug product offerings and its telesales programs and capabilities. Harvard Drug also

Harvard Drug Group sold to Cardinal

DUBLIN, Ohio — Cardinal Health Inc. plans to acquire pharmaceutical distributor The Harvard Drug Group (THDG) from private equity firm Court Square Capital Partners for $1.12 billion. Based in Livonia, Mich., THDG is a distributor of generic drugs, over-the-counter medicines and related products to retail, institutional and alternate care customers. THDG had revenue of about

Cardinal Health to acquire Cordis from J&J

DUBLIN, Ohio — Cardinal Health Inc. plans to acquire cardiology and endovascular device maker Cordis from Johnson & Johnson for $1.944 billion. Cardinal said Monday that the cash deal would significantly advance its offering of interventional cardiology and endovascular solutions for integrated health systems and their patients by giving the company immediate global scale in